Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Nancy A. Grygiel, Senior Vice President and Chief Compliance Officer at Amgen Inc . (NASDAQ:AMGN), recently sold shares of the company's common stock. According to a filing with the Securities and ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on Tuesday, February 4th. Analysts expect the company to announce earnings of $5.04 ...